Tentative first steps to eradicate latent HIV

Affiliations

¹ Department of Microbiology and Immunology, The University of Melbourne, Peter Doherty Institute for Infection and Immunity, VIC 3010, Australia.
² Centre for Vascular Research, UNSW Australia, Sydney, NSW, Australia.

Comment

Stephen J Kent et al. Lancet HIV. 2014 Oct.

. 2014 Oct;1(1):e2-3.

doi: 10.1016/S2352-3018(14)70015-3. Epub 2014 Sep 15.

¹ Department of Microbiology and Immunology, The University of Melbourne, Peter Doherty Institute for Infection and Immunity, VIC 3010, Australia.
² Centre for Vascular Research, UNSW Australia, Sydney, NSW, Australia.

No abstract available

Comment on

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.
Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Østergaard L, Søgaard OS. Rasmussen TA, et al. Lancet HIV. 2014 Oct;1(1):e13-21. doi: 10.1016/S2352-3018(14)70014-1. Epub 2014 Sep 15. Lancet HIV. 2014. PMID: 26423811